Lilly has announced a significant partnership with AI-driven Profluent Bio, aiming to advance genetic medicine through a deal potentially worth up to $2.25 billion. The collaboration focuses on developing innovative DNA editing tools to address genetic conditions that currently lack effective treatments.
The partnership will leverage Profluent's AI models to create site-specific recombinases—enzymes capable of precise DNA manipulation. Lilly will have exclusive rights to license and advance selected assets through various stages of development and commercialization. This initiative aims to enable the insertion of larger DNA segments, addressing the complexity of genetic diseases caused by multiple mutations.
Profluent's CEO, Ali Madani, emphasized the importance of kilobase-scale DNA editing as a breakthrough in genetic medicine, asserting that AI is crucial for developing the designer recombinases needed for targeted therapies. The agreement includes an undisclosed upfront payment, with Profluent eligible for further R&D funding and milestone payments based on development success.
This partnership reflects Lilly's ongoing commitment to integrating AI in its research strategies. Recent activities include a series of acquisitions in the oncology sector and collaborations with other AI-focused entities, positioning Lilly as a leader in the evolving landscape of genetic therapies. As the demand for precise genetic treatments grows, this alliance could pave the way for significant advancements in personalized medicine.